METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | XU, QING NILAR, SHAHUL ALT, CARSTEN RADEMACHER, PETER MICHAEL YEE, CALVIN WESLEY LI, ZHE |
| description | The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
L'invention concerne des composés inhibiteurs de la ferroportine de Formule (I) et des sels pharmaceutiques de ceux-ci, des méthodes de préparation des composés, des compositions pharmaceutiques comprenant les composés et des méthodes d'administration des composés pour la prophylaxie et/ou le traitement de maladies provoquées par un manque d'hepcidine ou des troubles du métabolisme du fer, en particulier des états de surcharge en fer, tels que la thalassémie, la drépanocytose et l'hémochromatose et également des lésions rénales. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3181583A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3181583A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3181583A13</originalsourceid><addsrcrecordid>eNrjZLDwdQ3x8HcJVvB3UwgNdlVw8w9SCIgM8vT1dPH0cw1WcAxWcHMNCvIP8A8K8fRT8PTz8HTyDPEPCuZhYE1LzClO5YXS3AxAhSHOHrqpBfnxqcUFicmpeakl8c6OxoYWhqYWxo6GxkQoAQAnhygy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS</title><source>esp@cenet</source><creator>XU, QING ; NILAR, SHAHUL ; ALT, CARSTEN ; RADEMACHER, PETER MICHAEL ; YEE, CALVIN WESLEY ; LI, ZHE</creator><creatorcontrib>XU, QING ; NILAR, SHAHUL ; ALT, CARSTEN ; RADEMACHER, PETER MICHAEL ; YEE, CALVIN WESLEY ; LI, ZHE</creatorcontrib><description>The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
L'invention concerne des composés inhibiteurs de la ferroportine de Formule (I) et des sels pharmaceutiques de ceux-ci, des méthodes de préparation des composés, des compositions pharmaceutiques comprenant les composés et des méthodes d'administration des composés pour la prophylaxie et/ou le traitement de maladies provoquées par un manque d'hepcidine ou des troubles du métabolisme du fer, en particulier des états de surcharge en fer, tels que la thalassémie, la drépanocytose et l'hémochromatose et également des lésions rénales.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211104&DB=EPODOC&CC=CA&NR=3181583A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25568,76551</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211104&DB=EPODOC&CC=CA&NR=3181583A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>XU, QING</creatorcontrib><creatorcontrib>NILAR, SHAHUL</creatorcontrib><creatorcontrib>ALT, CARSTEN</creatorcontrib><creatorcontrib>RADEMACHER, PETER MICHAEL</creatorcontrib><creatorcontrib>YEE, CALVIN WESLEY</creatorcontrib><creatorcontrib>LI, ZHE</creatorcontrib><title>METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS</title><description>The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
L'invention concerne des composés inhibiteurs de la ferroportine de Formule (I) et des sels pharmaceutiques de ceux-ci, des méthodes de préparation des composés, des compositions pharmaceutiques comprenant les composés et des méthodes d'administration des composés pour la prophylaxie et/ou le traitement de maladies provoquées par un manque d'hepcidine ou des troubles du métabolisme du fer, en particulier des états de surcharge en fer, tels que la thalassémie, la drépanocytose et l'hémochromatose et également des lésions rénales.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLDwdQ3x8HcJVvB3UwgNdlVw8w9SCIgM8vT1dPH0cw1WcAxWcHMNCvIP8A8K8fRT8PTz8HTyDPEPCuZhYE1LzClO5YXS3AxAhSHOHrqpBfnxqcUFicmpeakl8c6OxoYWhqYWxo6GxkQoAQAnhygy</recordid><startdate>20211104</startdate><enddate>20211104</enddate><creator>XU, QING</creator><creator>NILAR, SHAHUL</creator><creator>ALT, CARSTEN</creator><creator>RADEMACHER, PETER MICHAEL</creator><creator>YEE, CALVIN WESLEY</creator><creator>LI, ZHE</creator><scope>EVB</scope></search><sort><creationdate>20211104</creationdate><title>METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS</title><author>XU, QING ; NILAR, SHAHUL ; ALT, CARSTEN ; RADEMACHER, PETER MICHAEL ; YEE, CALVIN WESLEY ; LI, ZHE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3181583A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>XU, QING</creatorcontrib><creatorcontrib>NILAR, SHAHUL</creatorcontrib><creatorcontrib>ALT, CARSTEN</creatorcontrib><creatorcontrib>RADEMACHER, PETER MICHAEL</creatorcontrib><creatorcontrib>YEE, CALVIN WESLEY</creatorcontrib><creatorcontrib>LI, ZHE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>XU, QING</au><au>NILAR, SHAHUL</au><au>ALT, CARSTEN</au><au>RADEMACHER, PETER MICHAEL</au><au>YEE, CALVIN WESLEY</au><au>LI, ZHE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS</title><date>2021-11-04</date><risdate>2021</risdate><abstract>The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
L'invention concerne des composés inhibiteurs de la ferroportine de Formule (I) et des sels pharmaceutiques de ceux-ci, des méthodes de préparation des composés, des compositions pharmaceutiques comprenant les composés et des méthodes d'administration des composés pour la prophylaxie et/ou le traitement de maladies provoquées par un manque d'hepcidine ou des troubles du métabolisme du fer, en particulier des états de surcharge en fer, tels que la thalassémie, la drépanocytose et l'hémochromatose et également des lésions rénales.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3181583A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T08%3A06%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=XU,%20QING&rft.date=2021-11-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3181583A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |